Nader Rahimi

From Wikitia
Jump to navigation Jump to search
Nader Rahimi
Born (1963-12-22) December 22, 1963 (age 58)
Imperial State of Iran
NationalityIranian
CitizenshipCanada, United States
Education
  • University of Toronto (B.S.)
  • Queen's University (Ph.D.)
  • Harvard Medical School (Postdoc)
Scientific career
FieldsMolecular Biology, Receptor tyrosine kinases, posttranslational modification, Signal transduction
InstitutionsBoston University

Nader Rahimi (born December 22, 1963) is an Iranian born Molecular Biologist. He is currently Associate Professor at the Department of Pathology and Laboratory Medicine at Boston University.[1]. Google Scholar Page.

Education

Nader Rahimi received his Bachelor of Science degree in Biochemistry from the University of Toronto in 1991 and received his Ph.D. from Queen's University, Kingston, Canada in 1996. He completed his postdoctoral fellowship at Harvard Medical School in the fields of signal transduction and angiogenesis.

Career

Nader Rahimi has extensively published in the field of signal transduction by receptor tyrosine kinases in particular VEGF receptor tyrosine kinases. His notable works include demonstration of differential function of VEGFR-1 and VEGFR-2 in angiogenesis, identification of lysine methylation as a novel mechanism of activation of VEGFR-2, establishing protein ubiquitination as a major pathway modulating the angiogenic signaling of VEGFR-2[2][3][4][5]. He is also responsible for the discovery of multiple cell surface receptors including, IGPR-1[6][7][8][9], TMIGD1[10][11], MINAR1[12] and MINAR2[13]. His work on COVID-19 resulted in the discovery of CD209L and CD209 as novel receptors for SARS-COV-2[14]

Publications

  • Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells. 2020 07 09; 9(7). PMID: 32660065. READ AT: PubMed.
  • Amraie R, Napoleon MA, Yin W, Berrigan J, Suder E, Zhao G, Olejnik J, Gummuluru S, Muhlberger E, Chitalia V, Rahimi N. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. bioRxiv. 2020 Jun 23. PMID: 32607506. READ AT: PubMed.
  • Vasileva E, Shuvalov O, Petukhov A, Fedorova O, Daks A, Nader R, Barlev N. KMT Set7/9 is a new regulator of Sam68 STAR-protein. Biochem Biophys Res Commun. 2020 May 14; 525(4):1018-1024. PMID: 32178870. READ AT: PubMed.
  • Richards S, Walker J, Nakanishi M, Belghasem M, Lyle C, Arinze N, Napoleon MA, Ravid JD, Crossland N, Zhao Q, Rosenberg D, Rahimi N, Chitalia VC. Haploinsufficiency of Casitas B-Lineage Lymphoma Augments the Progression of Colon Cancer in the Background of Adenomatous Polyposis Coli Inactivation. Am J Pathol. 2020 03; 190(3):602-613. PMID: 32113662. READ AT: PubMed.
  • Lyle C, Richards S, Yasuda K, Napoleon MA, Walker J, Arinze N, Belghasem M, Vellard I, Yin W, Ravid JD, Zavaro E, Amraei R, Francis J, Phatak U, Rifkin IR, Rahimi N, Chitalia VC. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth. Sci Rep. 2019 12 27; 9(1):20257. PMID: 31882749. READ AT: PubMed.
  • Ho RX, Tahboub R, Amraei R, Meyer RD, Varongchayakul N, Grinstaff M, Rahimi N. The cell adhesion molecule IGPR-1 is activated by and regulates responses of endothelial cells to shear stress. J Biol Chem. 2019 09 13; 294(37):13671-13680. PMID: 31341021. READ AT: PubMed.
  • Chandler KB, Leon DR, Kuang J, Meyer RD, Rahimi N, Costello CE. N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2). J Biol Chem. 2019 08 30; 294(35):13117-13130. PMID: 31308178. READ AT: PubMed.
  • Brown Chandler K, Costello CE, Rahimi N. Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. Cells. 2019 Jun 05; 8(6). PMID: 31195728. READ AT: PubMed.
  • Kumaradevan S, Lee SY, Richards S, Lyle C, Zhao Q, Tapan U, Jiangliu Y, Ghumman S, Walker J, Belghasem M, Arinze N, Kuhnen A, Weinberg J, Francis J, Hartshorn K, Kolachalama VB, Cifuentes D, Rahimi N, Chitalia VC. c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/ß-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation. Am J Pathol. 2018 08; 188(8):1921-1933. PMID: 30029779. READ AT: PubMed.
  • Ho RX, Meyer RD, Chandler KB, Ersoy E, Park M, Bondzie PA, Rahimi N, Xu H, Costello CE, Rahimi N. MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth. J Mol Cell Biol. 2018 06 01; 10(3):195-204. PMID: 29329397. READ AT: PubMed.
  • Meyer RD, Zou X, Ali M, Ersoy E, Bondzie PA, Lavaei M, Alexandrov I, Henderson J, Rahimi N. TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer. Oncotarget. 2018 Feb 09; 9(11):9672-9684. PMID: 29515762. READ AT: PubMed.
  • Rahimi N. Defenders and Challengers of Endothelial Barrier Function. Front Immunol. 2017; 8:1847. PMID: 29326721. READ AT: PubMed.
  • Woolf N, Pearson BE, Bondzie PA, Meyer RD, Lavaei M, Belkina AC, Chitalia V, Rahimi N. Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy. Oncogenesis. 2017 Sep 18; 6(9):e378. PMID: 28920928. READ AT: PubMed.
  • Chandler KB, Leon DR, Meyer RD, Rahimi N, Costello CE. Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2. J Proteome Res. 2017 Feb 03; 16(2):677-688. PMID: 27966990. READ AT: PubMed.
  • Wang YH, Meyer RD, Bondzie PA, Jiang Y, Rahimi I, Rezazadeh K, Mehta M, Laver NM, Costello CE, Rahimi N. IGPR-1 Is Required for Endothelial Cell-Cell Adhesion and Barrier Function. J Mol Biol. 2016 Dec 04; 428(24 Pt B):5019-5033. PMID: 27838321. READ AT: PubMed.
  • Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016 11 01; 7(44):71136-71150. PMID: 27661103. READ AT: PubMed.
  • Nader Rahimi 24.03.2016. THERAPEUTIC AND RESEARCH APPLICATION OF PDCL3. 2016. READ AT.
  • Maghsoudlou A, Meyer RD, Rezazadeh K, Arafa E, Pudney J, Hartsough E, Rahimi N. RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR-2. Traffic. 2016 Mar; 17(3):289-300. PMID: 26602861. READ AT: PubMed.
  • Huang Z, Marsiglia WM, Basu Roy U, Rahimi N, Ilghari D, Wang H, Chen H, Gai W, Blais S, Neubert TA, Mansukhani A, Traaseth NJ, Li X, Mohammadi M. Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase C?. Mol Cell. 2016 Jan 7; 61(1):98-110. PMID: 26687682; PMCID: PMC4838190. READ AT: PubMed.
  • Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz JH, Chitalia V, Rahimi N. TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury. Am J Pathol. 2015 Oct; 185(10):2757-67. PMID: 26342724. READ AT: PubMed.

References

  1. https://www.bumc.bu.edu/busm-pathology/people_main/nader-rahimi-phd/
  2. https://www.researchgate.net/publication/38085465_A_role_for_protein_ubiquitination_in_BEGFR-2_signaling_and_angiogenesis
  3. Meyer, R. D.; Srinivasan, S.; Singh, A. J.; Mahoney, J. E.; Gharahassanlou, K. R.; Rahimi, N. (2011). "PEST Motif Serine and Tyrosine Phosphorylation Controls Vascular Endothelial Growth Factor Receptor 2 Stability and Downregulation". Molecular and Cellular Biology. 31 (10): 2010–2025. doi:10.1128/MCB.01006-10. PMC 3133358. PMID 21402774.
  4. https://www.pnas.org/content/104/13/5413
  5. Meyer, R. D.; Husain, D.; Rahimi, N. (2011). "C-CBL inhibits angiogenesis and tumor growth by suppressing activation of PLCγ1". Oncogene. 30 (19): 2198–2206. doi:10.1038/onc.2010.597. PMC 3969724. PMID 21242968.
  6. https://www.jbc.org/content/early/2019/07/24/jbc.RA119.008548.full.pdf
  7. Woolf, N.; Pearson, B. E.; Bondzie, P. A.; Meyer, R. D.; Lavaei, M.; Belkina, A. C.; Chitalia, V.; Rahimi, N. (2017). "Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy". Oncogenesis. 6 (9): e378–. doi:10.1038/oncsis.2017.77. PMC 5623903. PMID 28920928.
  8. Wang, Y. H.; Meyer, R. D.; Bondzie, P. A.; Jiang, Y.; Rahimi, I.; Rezazadeh, K.; Mehta, M.; Laver, N. M.; Costello, C. E.; Rahimi, N. (2016). "IGPR-1 is Required for Endothelial Cell-Cell Adhesion and Barrier Function". Journal of Molecular Biology. 428 (24 Pt B): 5019–5033. doi:10.1016/j.jmb.2016.11.003. PMC 5138093. PMID 27838321.
  9. Rahimi, N.; Rezazadeh, K.; Mahoney, J. E.; Hartsough, E.; Meyer, R. D. (2012). "Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis". Molecular Biology of the Cell. 23 (9): 1646–1656. doi:10.1091/mbc.E11-11-0934. PMC 3338432. PMID 22419821.
  10. Meyer, R. D.; Zou, X.; Ali, M.; Ersoy, E.; Bondzie, P. A.; Lavaei, M.; Alexandrov, I.; Henderson, J.; Rahimi, N. (2017). "TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/P27Kip1 in renal cancer". Oncotarget. 9 (11): 9672–9684. doi:10.18632/oncotarget.23822. PMC 5839393. PMID 29515762.
  11. Arafa, E.; Bondzie, P. A.; Rezazadeh, K.; Meyer, R. D.; Hartsough, E.; Henderson, J. M.; Schwartz, J. H.; Chitalia, V.; Rahimi, N. (2015). "TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury". The American Journal of Pathology. 185 (10): 2757–67. doi:10.1016/j.ajpath.2015.06.006. PMC 4607757. PMID 26342724.
  12. Ho, R. X.; Meyer, R. D.; Chandler, K. B.; Ersoy, E.; Park, M.; Bondzie, P. A.; Rahimi, N.; Xu, H.; Costello, C. E.; Rahimi, N. (2018). "MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth". Journal of Molecular Cell Biology. 10 (3): 195–204. doi:10.1093/jmcb/mjy002. PMC 6025234. PMID 29329397.
  13. https://academic.oup.com/braincomms/article/2/1/fcaa047/5823289
  14. https://www.mdpi.com/2073-4409/9/7/1652

This article "Nader Rahimi" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.